The National Innovation Office at the Federal Agency for Medicines and Health Products (FAMHP) has been launched in order to facilitate and support innovation in pharmaceutical research and development (R&D) in Belgium and the communication with the innovators.
The National Innovation Office is intended to serve as the central access point to the existing scientific and regulatory expertise of FAMHP both for human and veterinary medicines and therapies. The National Innovation Office is accessible for pharmaceutical companies, small and medium-sized enterprises (SMEs), academic research centres, spin-offs, academic hospitals and individuals who are actively involved in pharmaceutical innovation in general and particularly in research and development of new medicines and therapies.
The National Innovation Office offers tailor-made support mechanisms particularly to SMEs, academic research centres, spin-offs and academic hospitals.
The three main pillars of activities are:
- scientific, technical and regulatory advice;
- general innovation activities;
- support to SMEs and the academic sector.